Comparison of the efficacy and safety of bilastine 20 mgvslevocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study-Reference-Cited by-同舟云学术

Comparison of the efficacy and safety of bilastine 20 mgvslevocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study

Published:2010-04 Issue:4 Volume:65 Page:516-528
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:

Author:

Zuberbier T.,Oanta A.,Bogacka E.,Medina I.,Wesel F.,Uhl P.,Antépara I.,Jáuregui I.,Valiente R.,

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1398-9995.2009.02217.x/fullpdf

Reference37 articles.

1. Chronic Urticaria. Aetiology, management and current future treatment options;Kozel;Drugs,2004

2. Chronic idiopathic urticaria: prevalence and clinical course;Kulthanan;J Dermatol,2007

3. Chronic idiopathic urticaria;Greaves;Curr Opin Allergy Clin Immunol,2003

4. BSACI guidelines for the management of chronic urticaria and angio-oedema;Powell;Clin Exp Allergy,2007

5. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria;Zuberbier;Allergy,2006

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative inhibition by oral bilastine, parenteral dexchlorpheniramine, and a new bilastine parenteral (i.v. and i.m.) formulation of histamine-induced wheal and flare response: A randomised phase I trial;European Journal of Pharmaceutical Sciences;2024-12

2. Analyzing the clinical efficacy and safety of levocetirizine based on its receptor occupancy, intraclass comparison and role in the treatment of CSU: an AROG consensus statement;Expert Review of Clinical Pharmacology;2024-09-12

3. The Effect of Placebo on Pruritus in Patients with Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials;Clinical Drug Investigation;2024-09-06

4. Bioequivalence and Safety of Bilastine 20 mg Orodispersible Tablets and Conventional Tablets: A Randomized, Single-Dose, Two-Period Crossover Study in Healthy Volunteers Under Fasting Conditions;Drugs in R&D;2024-08-01

5. Adverse events of pegvaliase in the treatment of phenylketonuria: A pharmacovigilance study based on the FAERS database;2024-07-23